Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Vasculaire complicaties na niertransplantatie (DAN-PTRAIII)

12 oktober 2026 bijgewerkt door: University of Aarhus

Vasculaire complicaties na niertransplantatie: een prospectieve nationale multicenterstudie - de DAN-PTRAIII-studie

  • To determine the incidence of arterial inflow problems and venous outflow problems as causes of impaired renal function and/or treatment-resistant hypertension after kidney transplantation, when all kidney-transplant recipients in Denmark are evaluated according to uniform, well-defined clinical criteria.
  • To investigate the efficacy and safety of catheter-based balloon treatment (percutaneous transluminal angioplasty, PTA) for these vascular complications, of which transplant renal artery stenosis is by far the most common.
  • To assess whether novel imaging and functional diagnostic methods can predict treatment response.

Studie Overzicht

Gedetailleerde beschrijving

Kidney transplantation is performed 250-300 times annually in Denmark and substantially improves survival, quality of life, and reduces the burden of comorbidities in patients with end-stage kidney disease. Despite these benefits, vascular complications, particularly transplant renal artery stenosis (TRAS), remain a major cause of morbidity. Reported incidence of TRAS varies widely (1-23%), reflecting retrospective study designs and inconsistent diagnostic criteria. TRAS are classified into three main types: anastomotic (TRAS-A), post-anastomotic (TRAS-P), and long-segment bend/kink (TRAS-B), with most cases diagnosed within the first two years post-transplant. Severe stenoses can critically impair graft perfusion, leading to reduced renal function and treatment-resistant hypertension.

Percutaneous transluminal angioplasty (PTA) for TRAS is a well-established procedure performed according to the same principles as coronary balloon angioplasty; however, the role of stent placement remains uncertain. PTA without stenting is associated with higher restenosis rates compared to PTA with stenting, yet evidence regarding graft function, survival, and blood-pressure control remains conflicting.

Adverse events related to PTA occur in approximately 10% of patients and are generally mild. Serious adverse events are observed in fewer than 5% of patients and include procedure-related internal bleeding and vascular access-site complications. Severe internal bleeding may require blood transfusion and endovascular vessel occlusion and can, in rare cases, result in loss of the transplanted kidney. Access-site vascular complications may present as bleeding, thrombosis, or pseudoaneurysm.

Against this background, the nationwide prospective multicentre DAN-PTRAIII study aims to establish the true incidence of arterial inflow and venous outflow problems in Danish kidney-transplant recipients, evaluate the efficacy and safety of balloon angioplasty, and explore novel imaging and functional diagnostic methods for predicting treatment response.

Studietype

Observationeel

Inschrijving (Geschat)

60

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Mark Reinhard, MD, PhD
  • Telefoonnummer: +45 40460321
  • E-mail: markrein@rm.dk

Studie Contact Back-up

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

National prospective multicenter study with a primary endpoint at 3 months and annual follow-up for up to 10 years post-intervention, evaluating renal function, blood pressure, and clinical events.

Patients with vascular complications, predominantly transplant renal artery stenosis (TRAS) following kidney transplantation, who meet at least one of the clinical inclusion criteria, may be enrolled in the study.

Beschrijving

Inclusion Criteria:

1. At least one of the following clinical criteria (1 or 2) must be fulfilled:

  1. Graft dysfunction, defined by at least one of the following:

    • Acute reduction in estimated glomerular filtration rate (eGFR) >15% on two consecutive measurements at least 2 weeks apart, with other causes excluded (rejection, obstruction, infection).
    • eGFR <50% of the expected value 30 days after kidney transplantation of unknown cause.
    • Decline in eGFR >30% after initiation of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.
  2. Persistent resistant hypertension for more than 6 weeks after kidney transplantation, defined as:

    • 24-hour ambulatory systolic blood pressure >130 mmHg despite treatment with at least three classes of antihypertensive medication at maximally tolerated doses (including diuretics, if tolerated).

Together with at least one of the following radiological criteria:

  1. CT or MR angiography demonstrating a lumen reduction ≥50%.

  2. Doppler ultrasound showing:

    1. Peak systolic velocity in the renal artery ≥200 cm/s and a renal-renal ratio (velocity at stenosis / velocity in distal artery) >4.
    2. Acceleration time >70 ms in intrarenal arteries.

2. In cases of strong clinical suspicion of a vascular complication where CT or MR angiography cannot reliably exclude graft artery or vein stenosis, patients may be referred for confirmatory invasive investigations.

Before PTA, catheter-based angiography and translesional pressure measurements are performed to confirm whether the patient meets the radiological eligibility criterion for PTA:

  1. Stenosis ≥70%.

  2. Stenosis 50-69% if at least one of the following criteria is met:

    • Mean translesional pressure gradient ≥10 mmHg.
    • Systolic pressure gradient ≥20 mmHg.
    • Renal Pd/Pa ≤0.8.
    • If pressure measurements cannot be obtained, treatment is based on the operator's clinical judgement.

Exclusion Criteria:

  1. Inability to provide informed consent.
  2. Concurrent biopsy demonstrating rejection requiring treatment.
  3. Pregnancy.
  4. Previous PTA of the same vessel.
  5. Patients unable to tolerate any form of antithrombotic therapy and therefore not eligible for stent placement.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Kidney Transplant Recipients

Patients who meet well-defined clinical and radiological criteria for significant vascular complications after kidney transplantation, with transplant renal artery stenosis being by far the most common.

Catheter-based angiography performed in accordance with the study protocol.

Measurement of translesional pressure gradients performed in accordance with the study protocol.

Intravascular ultrasound (IVUS) performed in accordance with the study protocol.

Percutaneous transluminal angioplasty (PTA) is performed in accordance with the study protocol. As a general principle, bare-metal stents (BMS) are used. Drug-eluting stents (DES) may be considered when the arterial lumen diameter is < 4-5 mm. In stenoses where stent placement carries a risk of side-branch occlusion, PTA is performed without stent implantation and most often with a drug-coated balloon (DCB).

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in measured glomerular filtration rate (mGFR).
Tijdsspanne: Baseline and 3 months post-PTA.

Change in measured glomerular filtration rate (mGFR) at 3 months post-PTA compared with baseline.

Baseline and 3 months post-PTA.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in estimated glomerular filtration rate (eGFR).
Tijdsspanne: Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.

Change in estimated glomerular filtration rate (eGFR) measured on day 1, day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline.

Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
Change in home systolic blood pressure.
Tijdsspanne: Baseline, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.

Change in home systolic blood pressure measured on day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline.

Baseline, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
Change in attended automated office systolic blood pressure.
Tijdsspanne: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in attended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in unattended automated office systolic blood pressure.
Tijdsspanne: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in unattended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in 24-hour ambulatory systolic blood pressure.
Tijdsspanne: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in defined daily dose (DDD) of antihypertensive medications.
Tijdsspanne: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in defined daily dose (DDD) of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in the number of antihypertensive medications.
Tijdsspanne: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in the number of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in 24-hour ambulatory systolic blood pressure adjusted for changes in antihypertensive medication.
Tijdsspanne: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline, adjusted for changes in antihypertensive medication (5 mmHg per DDD).

Baseline, 3 months, 12 months, and 24 months post-PTA.
Health status on 12-item Short Form Health Survey (SF-12).
Tijdsspanne: Baseline and 3 months post-PTA.

Change in 12-item Short Form Health Survey (SF-12) scores at 3 months post-PTA, compared with baseline.

Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

Baseline and 3 months post-PTA.
Number of clinical events after PTA.
Tijdsspanne: 10 years post-PTA.

Cardiovascular and renal events are defined according to the criteria used in the DAPA-CKD study, with the modification that end-stage kidney disease is defined exclusively as either kidney transplantation or chronic dialysis. After PTA treatment, the following clinical events will be recorded for 10 years:

  1. Cardiovascular death
  2. Renal death
  3. Death from non-cardiovascular and non-renal causes
  4. Undetermined cause of death
  5. Stroke
  6. Myocardial infarction
  7. Hospitalization for heart failure
  8. Reduction in eGFR ≥50% from baseline for ≥28 days, not fulfilling the definition of end-stage kidney disease
  9. End-stage kidney disease, defined as kidney transplantation or chronic dialysis for ≥28 days
  10. Biopsy-proven rejection
  11. Need for repeat PTA due to restenosis or in-stent thrombosis
  12. Other relevant clinical events
10 years post-PTA.
Number of adverse events (AEs) occurring within 30 days after the procedure
Tijdsspanne: 30 days post-PTA.

All adverse events (AEs) occurring within 30 days after the procedure will be recorded and classified according to seriousness, relationship to the procedure, and whether the event occurs within ≤24 hours (periprocedural) or >24 hours through day 30 (post-interventional):

  1. Vessel rupture
  2. Vessel dissection
  3. Vessel occlusion
  4. Vessel perforation
  5. Stent thrombosis
  6. Embolic events to the kidney or the peripheral circulation (upper or lower extremity, depending on the access route)
  7. Pulmonary oedema
  8. Major bleeding requiring transfusion
  9. Embolisation due to bleeding or another adverse event
  10. Nephrectomy due to bleeding or another adverse event
  11. Access-site or access-vessel complication requiring additional hospitalisation, blood transfusion, or surgical intervention
  12. Requirement for acute dialysis
  13. Clinical events, including all-cause mortality, as defined above
  14. Other relevant adverse events (AEs)
30 days post-PTA.
Doppler ultrasound.
Tijdsspanne: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Invasive pressure measurements across stenoses.
Tijdsspanne: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Intravascular ultrasound.
Tijdsspanne: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Non-invasive fractional flow reserve computed tomography (FFR-CT) / computational fluid dynamics (CFD) simulation.
Tijdsspanne: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Functional magnetic resonance imaging.
Tijdsspanne: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

22 mei 2026

Primaire voltooiing (Geschat)

31 maart 2031

Studie voltooiing (Geschat)

1 juni 2031

Studieregistratiedata

Eerst ingediend

1 april 2026

Eerst ingediend dat voldeed aan de QC-criteria

13 april 2026

Eerst geplaatst (Werkelijk)

15 april 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

12 oktober 2026

Laatst geverifieerd

1 mei 2026

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren